Monday, 24 July 2017

India's Kemwell acquires US-based CRO Cirrus

01 August 2013 | News | By BioSpectrum Bureau

The financial details of the deal have not been disclosed yet

The financial details of the deal have not been disclosed yet

Singapore: Indian contract pharmaceutical development and manufacturing firm Kemwell Biopharma has acquired US contract research and product development company Cirrus Pharmaceuticals to expand its product portfolio and market reach. The financial details of the deal have not been disclosed yet.

"Cirrus will complement the existing contract services offered by Kemwell for early-stage innovative product development. Kemwell will now provide customers with complete solutions - from early development in the US to commercial manufacturing in Kemwell's EMA, FDA and PMDA-approved facilities in India and Sweden," Mr Anurag Bagaria, chairman and managing director, Kemwell.

Cirrus provides R&D services including physical and chemical characterization, formulation development, stability testing, container selection, process development, scale-up and technical transfer for inhaled, nasal, oral, parenteral, topical and transdermal products.

"With Cirrus' development capabilities and Kemwell's manufacturing expertise, we will be able to develop products with faster time-to-clinic and significant cost savings for our customers," said Dr Ninad Deshpanday, R&D president, Kemwell.

"This acquisition will transform Cirrus into a global player in R&D services by significantly strengthening our capabilities in inhalation R&D and increasing offerings in other areas such as oral solids dosage forms," said Mr Anthony Hickey, president, Cirrus.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account

Survey Box

Is value- based patient healthcare system more effective in Asian countries?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls